ASCIA HAE Position Paper and Management Plan

The management of hereditary angioedema (HAE) is evolving, with more options for long-term prophylaxis that are now available. The ASCIA HAE position paper and management plan were updated in early 2020 to include these new treatments and to be consistent with international guidelines.  These changes are explained in an ASCIA Webinar about  HAE that was presented on 30 March 2020. An update to page 12 was made in July 2020, in response to the new product registration in New Zealand for prophylaxis of HAE attacks.
Updated ASCIA HAE Position Paper 2020
pdfASCIA HP Position Paper HAE 2020734.10 KB

New ASCIA HAE Management Plan 2020 (with type in fields), which replaces the ASCIA HAE Action Plan.
pdfASCIA HAE Management Plan 2020129.80 KB

New ASCIA HAE Case Peer Review Form (with type in fields), which needs to be completed when requesting prophylaxis dose increases using a new treatment option - Berinert® SC.
pdfASCIA HAE Case Peer Review Form 202091.69 KB

ASCIA Hereditary Angioedema Position Paper 2020  ASCIA Management Plan HAE 2020  ASCIA HAE Case Peer Review Form 2020

Notice from Cipla regarding supply of icatibant

pdfCipla Icatibant Information109.55 KB

Notice from Takeda regarding delisting of Firazyr (icatibant) from PBS in Australia. 

pdfHCP_letter_Firazyr_PBS_Update_002726.08 KB

For information regarding supply of danazol in Australia please refer to  
ASCIA HAE Working Party members are listed at 

HAE Australasia is a support organisation for people with HAE and their carers in Australia and New Zealand.  For more information visit 

For information about how ASCIA information for health professionals is developed go to:

Content updated December 2020